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Blood and lymphatic vessel formation is an indispensa-
ble factor for cancer progression and metastasis. There-
fore, various strategies designed to block angiogenesis 
and lymphangiogenesis are being investigated in the 
hope to arrest and reverse tumor development. Mono-
clonal antibodies, owing to their unequalled diversity 
and specificity, might be applied to selectively inhibit 
the pathways that cancer cells utilize to build up a net-
work of blood vessels and lymphatics. Among the pos-
sible targets of antibody-based therapies are proangio-
genic and prolymphangiogenic growth factors from the 
VEGF family and the receptors to which they bind (VEG-
FRs). Here, we present molecular mechanisms of angio-
genesis and lymphangiogenesis exploited by tumors to 
progress and metastasise, with examples of antibody-
based therapeutic agents directed at interfering with 
these processes. The expanding knowledge of vascular 
biology helps to explain some of the problems encoun-
tered in such therapies, that arise due to the redundancy 
in signaling networks controlling the formation of blood 
and lymphatic vessels, and lead to tumor drug resist-
ance. Nonetheless, combined treatments and treatments 
focused on newly discovered proangiogenic and prolym-
phangiogenic factors give hope that more prominent 
therapeutic effects might be achieved in the future.
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INTRoducTIoN
Cancer is the leading cause of death in developed 
countries. Although localized tumors are successfully 
treated by surgery, radiotherapy and other more selective 
methods, medicine is often helpless in the face of meta-
static disease — the most lethal form of cancer. There-
fore, enormous efforts are being made to create spe-
cific agents with a potential to suppress tumor growth 
and prevent the processes that cause benign tumors to 
gain metastatic competence and begin to spread to dis-
tant organs. Progression from benign to malignant tu-
mor involves an increase in tumor cell proliferation rate 
and in the ability to migrate and invade other tissues. 
Metastatic tumor cells utilize blood and lymph vessels as 
routes for dissemination. Tumor-derived factors stimu-
late formation of new blood vessels (angiogenesis) and 
lymph vessels (lymphangiogenesis), which actively sup-
port tumor growth and spreading. Different approaches 
are applied to inhibit tumor progression. This review will 
particularly focus on antibody-based therapies inhibiting 
proangiogenic and prolymphangiogenic signals mediated 
by endothelial cell growth factors and their receptors. An 
overview of potential targets for therapeutic monoclonal 
antibodies in these processes is shown in Table 1. In 
the future, strategies utilizing such antibodies, alone or 
combined with other antitumor therapies, may become a 
method of choice in the treatment of metastatic cancers.
RolE oF ANGIoGENEsIs IN cANcER pRoGREssIoN
Angiogenesis is a process involving formation of new 
blood vessels from preexisting ones. Over forty years 
ago, Judah Folkman hypothesized that the process of 
angiogenesis is critical for tumor growth: solid tumors 
need to develop new blood vasculature to obtain nu-
trients and oxygen they need to survive and proliferate 
(Folkman, 1971). Angiogenesis is also an essential com-
ponent of the metastatic process. Tumor vasculature is 
a route by which malignant cells exit the primary site to 
enter general circulation and establish new foci in dis-
tant organs. The newly formed blood vessels are imma-
ture and leaky, and may not form continuous layer that 
would prevent intravasation of cancer cells.
Blood vessels are also a dynamic structure connect-
ing tumor environment with the host immune system. 
Tumor endothelial cells (TECs) interact with the extra-
cellular matrix and stromal tumor cells as well as with 
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Table 1. Monoclonal antibodies as inhibitors of lymph- and angiogenesis
Target Name Type Description Research phase
Antiangiogenic action
VEGF-A Bevacizumab humanized IgG1 
[1]
binds to VEGF-A and inhibits its biological acti-
vity [1]
approved for co-
lorectal cancer, 
NSCLC*, renal cell 
carcinoma, gliobla-
stoma [1]
VEGFR-2 Ramucirumab human IgG1 [2]
blocks VEGF ligand (VEGF-A, VEGF-C and VEGF-D) 
binding to VEGFR-2 [2]
Phase 3 breast 
cancer, gastric 
cancer, hepatocel-
lular carcinoma, 
NSCLC,gastric 
cancer, colorectal 
cancer [3]
VEGFR-2 Tanibirumab human IgG1 [4]
blocks VEGF ligand (VEGF-A, VEGF-C and VEGF-D) 
binding to VEGFR-2 [4]
preclinical studies, 
animal models[4]
Dll-4 (Notch Delta-
-like ligand 4)
YW152F humanized Ig [5]
neutralizes Dll-4, induces endothelial cell hyper-
proliferation and formation of defective vessels 
[5] when Dll4-Notch signaling is blocked, there 
is a decreased tumor growth and a reduction in: 
bone marrow-derived pericytes, vascular smooth 
muscle cell formation, vessel functionality, lu-
men-bearing vessels [6]
preclinical studies, 
animal models [5,6]
HK (high molecular 
weightkininogen)
C11C1 murine IgG1 [7]
inhibits angiogenesis by reducing tumor mi-
crovascular density andblocks binding of HK to 
endothelial cells [8]
preclinical, animal 
models [7,8]
EphB4 (Ephrin type-
-Breceptor 4)
hAb47 and 
hAb131
humanized IgG1 
[9]
hAb131 induces degradation of human EphB4, 
inhibits human endothelial tube formation in 
vitro and growth of human tumors expressing 
EphB4 in vivo hAb47 targets human and murine 
EphB4, inhibits angiogenesis and growth of both 
EphB4-positive and EphB4-negative tumors in 
amouse model [9]
preclinical, animal 
models [9]
globotriaosylcera-
mide Gb3
3E2 murine IgM [10]
inhibits: endothelial cell proliferation in vitro, 
angiogenesis ex vivo, neuroblastoma develop-
ment and liver metastase spreading in murine 
models [10]
preclinical, animal 
models [10]
YKL-40secreted 
glycoprotein
mAY murine Ig [11]
inhibits tube formation of microvascular endo-
thelial cells in vitro,prevents YKL-40-induced ac-
tivation of VEGFR-2, restrains tumor growth and 
angiogenesis in animal models [11]
preclinical, animal 
models [11]
Ang-2 (angiopoie-
tin-2)
LC06 human IgG1 [12]
prevents binding of Ang-2 to its receptor Tie2, 
inhibits tumor growth, reduces: intratumoral 
microvessel density, tumor vessel branching and 
dissemination of tumor cells to the lungs, incre-
ases pericyte coverage [12] coverage [12]
preclinical studies, 
animal models [12]
Ang-2 (angiopoie-
tin-2)
MEDI3617 human Ig [13]
prevents Ang-2 bindisng to the Tie2 receptor in 
vitro, inhibits angiogenesis and tumor growth in 
vivo [13]
preclinical studies, 
animal models 
[13, 14]
HB-EGF(heparin-
-binding EGF-like 
growth factor)
Y-142 murine Ig [15] inhibits sHB-EGF-induced cancer cell proliferation 
and sHB-EGF- induced angiogenesis [15]
in vitro studies [15]
Antiangiogenic and antitumor action
EGFR Cetuximab
chimeric human/
mouse IgG1[16]
EGFR antagonist [16], may reduce pro-angiogenic 
factor secretion by cancer cells [17] cancer cells 
[17]
approved for head 
and neck cance-
rand colorectal 
cancer [16]
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EGFR Panitumumab human IgG2 [18]
human IgG2 competitively inhibits binding of 
ligands (eg. EGF, TGFα) to EGFR [18]
approved for me-
tastatic colorectal-
cancer [18] Phase 
3 (head and neck 
cancer) Phase 2 
(pancreatic cancer) 
[19]
HER2 Trastuzumab
humanized IgG1 
[20]
mediator of ADCC [20]
approved for me-
tastatic breast and 
gastric cancers [20]
HER2 Pertuzumab
humanized IgG1 
[21]
blocks ligand-dependent dimerization of target 
receptor, mediator of ADCC [21]
approved for bre-
ast cancer [22]
VEGFR-1 Icrucumab human IgG1 [23]
blocks VEGF-A, VEGF-B and PlGF binding to 
VEGFR-1; inhibits VEGFR-1 activation in both 
cancer and non malignant supporting cells that 
contribute to tumor progression [23]
Phase 2, colorec-
tal cancer, breast 
cancer, bladder, 
urethra, ureter, and 
renal pelvis carci-
noma [24]
PDGFRα
Olaratumab, IMC-
-3G3
human IgG1 [25]
targets PDGFRα present on both tumor and 
stromal cells, inhibits tumor and vasculature for-
mation [25, 26]
Phase 2NSCLC, soft 
tissue sarcoma, 
prostate cancer 
[27]
integrin α5β1 Volociximab
chimeric human/
mouse IgG4 [28]
human/mouse chimeric antibody, inhibits endo-
thelial cell proliferation and formation of capillary 
like structures by endothelial cells, inhibits tumor 
growth in vivo [28]
Phase 1b/2NSCLC 
[29]
Notch1 anti-NRR1 human IgG1 [30]
specific toward negative regulatory region (NRR) 
of Notch1; stabilizes NRR quiescence, inhibits 
cancer cell growth and disrupts tumor angioge-
nesis, blocks both ligand-dependent and -inde-
pendent Notch activation [30]
preclinical studies, 
animal models [30]
HER2 chA21
single-chain chi-
meric antibody 
[31]
it does not directly disrupt dimerization of tar-
get receptor but leads to its internalization and 
down-regulation [31] inhibits VEGF secretion and 
down-regulates migration and proliferation of 
endothelial cells [32]
preclinical, animal 
models [32]
Antilymphangiogenesis
VEGFR-3 IMC-3C5 human IgG1 [33]
blocks VEGF-C and VEGF-D binding to VEGFR-3; 
inhibits mitogenic response to mature VEGF-C 
[33]
Phase 1 [34]
VEGF-C VGX-100 human Ig [35]
human Ig, blocks VEGF-C binding to VEGFR-2 and 
VEGFR-3 [35]
Phase 1 [36]
ephrinB2 B11, 2B1
human single-
-chain variable 
fragments [37]
suppresses endothelial cell migration and tube 
formation in vitro, reduces tumor growth and 
inhibits lymph- and angiogenesis in animal mo-
dels [37]
preclinical, animal 
models [37]
VEGF-D cVE199 chimeric IgG1 [38] inhibits VEGF-D binding to VEGFR-3 [38]
preclinical studies, 
animal models[38]
VEGFR-3 2E11 –
inhibits formation of VEGFR-3 homodimers and 
VEGFR-3/VEGFR-2 heterodimers but does not 
inhibit binding of VEGF-C to VEGFR-3 [39]
preclinical studies, 
animal models[39]
Nrp2 – –
blocks VEGF-C binding to Nrp2 and disrupts lym-
phatic endothelial
preclinical studies, 
animal models
(Neuropilin-2) cell migration [40] [40]
VEGF-C VC2
human single-
-chain variable 
fragment [41]
dose-dependently inhibits the binding of VEGF-C 
to VEGFR-2 and VEGFR-3 [41]
in vitro studies [41]
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immune cells (Berezhnaya, 2010). They also control leu-
kocyte recruitment and may contribute to the immune 
escape of tumors (Bussolati et al., 2003; Chouaib et al., 
2010). For many years, it was thought that biological 
properties of TECs are identical or similar to those of 
endothelial cells from healthy tissue. However, recent 
studies on isolated TECs revised this hypothesis. TECs 
are described as “chronically activated or inflamed” 
(Dudley, 2012). Tumor cells produce many factors, such 
as TNF, which stimulate expression of adhesion mole-
cules Thy-1, E- selectin, NCAM (Bussolati et al., 2003) 
on the endothelial cells. Activated endothelium recruits 
proinflammatory cells, in particular macrophages, which 
might contribute to angiogenesis and tumor progression.
The role of VEGF/VEGFR signaling in tumor 
development and metastasis
New blood vessel formation is a complex process reg-
ulated by numerous proangiogenic modulators, among 
which the vascular endothelial growth factor-A (further 
referred to as VEGF) seems to play a predominant role. 
VEGF, also known as vascular permeability factor, is a 
key angiogenic factor that regulates both normal and tu-
mor angiogenesis (Ferrara & Gerber, 2001). It belongs to 
the VEGF family of ligands that consists of seven mem-
bers: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-
E, VEGF-F and the placental growth factor (PlGF). 
These ligands exert their biological activity upon bind-
ing to tyrosine kinase receptors VEGFRs (VEGFR-1, 
VEGFR-2 and VEGFR-3). Activation of VEGFR-1 and 
VEGFR-2 signaling leads to migration of hematopoietic 
cells and growth, migration and survival of vascular en-
dothelial cells (Ferrara et al., 2003; Ferrara, 2004).
VEGF is overexpressed in tumors compared to nor-
mal tissues. It is secreted not only by tumor cells but 
also by tumor-associated stromal cells in response to hy-
poxic conditions in pathologically expanding tumor tis-
sue. VEGF induces angiogenesis by activating signaling 
through VEGFR in the blood vessels surrounding the 
tumor (Fukumura et al., 1998).
Expression of VEGF in solid tumors stimulates new 
blood vessel formation, which is crucial for the contin-
ued tumor growth as well as for metastasis. Addition-
ally, expression of VEGFR-2, a major receptor involved 
in malignant angiogenesis, is upregulated several-fold 
in tumor vascular endothelial cells (Plate et al., 1994). 
VEGFR-2 is also expressed on immune cells and, after 
its activation by VEGF, plays an important role as a fac-
tor suppressing anti-tumor immunity (Ohm & Carbone, 
2001; Suzuki et al., 2010). Many studies demonstrated 
that a high level of plasma VEGF correlated with dis-
ease progression, resistance to chemotherapy and poor 
prognosis for cancer patients (Lee et al., 2000; Poon et 
al., 2001).
VEGF is a critical survival factor for tumor endothe-
lial cells; therefore a constant supply of VEGF to the 
tumor is essential not only for the development of new 
tumor vasculature but also for the maintenance of blood 
vessels that already exist within the tumor. In the light 
of these data it has been proposed that the VEGF/
VEGFR axis could be a potential target for developing 
antiangiogenic and anticancer therapy. However, it is 
clear that antiangiogenic therapy should not only focus 
on tumor endothelium; other cells participating in new 
blood vessel formation like pericytes, fibroblasts, stromal 
cells and bone marrow-derived endothelial progenitor 
cells also seem to constitute valuable targets. It should 
also be noted that a growing body of evidence indicates 
the significant role not only of blood vessels but also of 
the lymphatic vessel system in tumor progression. Tu-
mor cells infiltrating the draining lymph nodes (dLNs) 
are regarded as an important diagnostic factor indicative 
of the stage and malignancy of the disease.
RolE oF lyMpHANGIoGENEsIs IN cANcER 
pRoGREssIoN
The lymphatic vessel system is composed of blind-
ended initial lymphatics, precollecting vessels, collecting 
vessels and the thoracic duct. One of its major physi-
ological roles is to maintain tissue fluid balance by drain-
ing protein-rich fluid from the interstitial space and driv-
ing it back to the blood circulation. Lymphatic vessels 
are also involved in the immune response. They are re-
MT1-MMP (MMP-
14, matrix metallo-
protease-14)
9E8 murine IgG1 [42]
blocks the enzymes ability to activate proMMP-2 
without interfering with the general proteolytic 
activity of MT1-MMP, inhibits outgrowth of lym-
phatic endothelial cells in vitro and lymphatic 
vessel sprouting ex vivo [42]
in vitro studies [42]
VEGFR-2 and 
VEGFR-3
– human diabody 
constructed of 
two human single-
-chain variable 
fragments [43]
directed against VEGFR-2 and VEGFR-3, inhibits 
activation of both receptors [43]
in vitro studies [43]
[1] (Roche, Avastin prescribing information, 2013; access on 26.03.2013; www.gene.com/download/pdf/avastin_prescribing.pdf), [2] (Zhu et al., 
2003), [3] (ClinicalTrials.gov identifiers: breast cancer NCT00703326, gastric cancer NCT00917384, hepatocellular carcinoma NCT01140347, NSCLC 
NCT01168973, gastric cancer NCT01170663, colorectal cancer NCT01183780), [4] (Lee, 2011), [5] (Ridgway et al., 2006), [6] (Stewart et al., 2011), [7] 
(Song et al., 2004), [8] (Khan et al., 2010), [9] (Krasnoperov et al., 2010), [10] (Desselle et al., 2012), [11] (Faibish et al., 2011), [12] (Thomas et al., 2013), 
[13] (Leow et al., 2012), [14] (Holopainen et al., 2012), [15] (Sato et al., 2012), [16] (Merc, Erbitux prescribing information, 2012), [17] (Perrotte et al., 
1999), [18] (Amgen, Panitumumab prescribing information, 2013; access on 26.03.2013; www.pi.amgen.com/united_states/vectibix/vectibi x_pi.pdf), 
[19] (ClinicalTrials.gov identifiers: head and neck cancer NCT00460265, pancreatic cancer NCT01175733), [20] (Roche, Herceptin prescribing informa-
tion, 2010; access on 26.03.2013; www.herceptin.com/pdf/herceptin-prescribing.pdf), [21] (El-Sahwi, 2010), [22] (Roche, Perjeta prescribing infor-
mation, 2012; access on 26.03.2013; www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf), [23] (Wu et al., 2006), [24] (ClinicalTrials.
gov identifiers: colorectal cancer NCT01111604, breast cancer NCT01234402, bladder, urethra, ureter, and renal pelvis carcinoma NCT01282463), 
[25] (Shah et al., 2010), [26] (Gerber et al., 2012), [27] (ClinicalTrials.gov identifiers: NSCLC NCT00918203,soft tissue sarcoma NCT00918203, prostate 
cancer NCT01204710), [28] (Bhaskar et al., 2008) , [29] (Besse et al., 2013), [30] (Wu et al., 2010), [31] (Zhou et al., 2011), [32] (Shen et al., 2011), [33] 
(Persaud et al., 2004), [34] (ClinicalTrials.gov identifier: NCT01288989), [35] (Hajrasouliha et al., 2012), [36] (ClinicalTrials.gov identifier: NCT01514123), 
[37] (Abengozar et al., 2012), [38] (Kashima et al., 2012), [39] (Tvorogov et al., 2010), [40] (Caunt et al., 2008), [41] (Rinderknecht et al., 2010), [42] 
(Ingvarsen et al., 2013), [43] (Jimenez et al., 2005).
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sponsible for the transport of antigens and constitute a 
route for antigen-presenting dendritic cells leading from 
peripheral tissues to the dLNs (Lund & Swartz, 2010). 
Tumor lymphatic vessels are also engaged in the trans-
port of tumor-derived growth factors and other proteins 
to the local lymph nodes. There they can exert immu-
nosuppressive or immunomodulatory effects, facilitating 
evasion of tumor cells from the immune surveillance 
(Lund et al., 2012).
Formation of the lymph vessel system takes place dur-
ing embryonic development. In adults, the growth of 
new lymphatic vessels occurs during inflammation and 
wound healing. Excessive lymphangiogenesis is observed 
in chronic inflammation, autoimmune disorders, graft re-
jection and, as it will be discussed in this review, in tu-
mor progression (Alitalo, 2011).
Although the importance of the lymphatic system for 
tumor development and spreading has been generally ac-
cepted for many years, deeper insight into the biology of 
the lymphatics has long been hampered due to the lack 
of defined lineage-specific markers.
The discovery of such markers for the lymphatic en-
dothelial cells (LECs): Lyve-1 (Banerji et al., 1999), Prox1 
(Wigle & Oliver, 1999), and podoplanin (Breiteneder-Gel-
eff et al., 1999), enabled significant progress in understand-
ing the mechanisms responsible for lymphatic-dependent 
metastasis. It is now well documented that lymphangi-
ogenesis induced by the growing tumor allows cancer 
cells to metastasise to the dLNs (Christiansen & Detmar, 
2011). Thus, lymphatic vessels are now considered one of 
the major routes for tumor cell spreading from primary 
sites to lymph nodes and, further, to distant tissues.
prolymphangiogenic growth factors
Data from in vitro as well as from in vivo experiments 
point at VEGF-C and VEGF-D as major growth factors 
driving tumor-dependent lymphangiogenesis through ac-
tivation of VEGFR-3 and its coreceptor neuropilin 2 
(Nrp2) (Makinen et al., 2001; Mandriota et al., 2001; Kar-
panen et al., 2006; Xu et al., 2010; Chen, et al., 2012). 
Since VEGF-C and VEGF-D can also activate VEG-
FR-2, they are considered proangiogenic factors as well 
(Leppanen et al., 2010). VEGF-C and VEGF-D produced 
by tumor cells along with tumor-infiltrating macrophag-
es stimulate LEC proliferation, survival, and migration 
(Makinen et al., 2001; Schoppmann et al., 2002; Otrock 
et al., 2007). VEGF-C has also been shown to stimulate 
LECs to express CCL21 and CCL19, chemokines which 
attract CCR7-positive tumor cells to the lymph vessels. 
As a result of this observation, LECs are now consid-
ered active players in tumor metastasis (Issa et al., 2009). 
The roles attributed to VEGF-C regarding tumor devel-
opment are presented in Fig. 1.
The results of in vivo experiments are even more con-
vincing. VEGF-C significantly increased intratumoral 
lymphangiogenesis in a breast cancer model and the ex-
tent of this process correlated with the dLN and lung 
metastasis (Skobe et al., 2001). In B16 melanoma model, 
overexpression of VEGF-C resulted in increased lym-
phangiogenesis around the tumor and metastasis to the 
dLNs (Lund et al., 2012). Similar correlation between 
VEGF-D-stimulated lymphangiogenesis and dLN me-
tastasis was also reported (Stacker et al., 2001). These 
observations are in accordance with the results of in 
vivo experiments in which the VEGF-C/VEGFR-3 axis 
has been blocked. The silencing of VEGF-C and/or 
VEGFR-3 expression resulted in decreased metastasis 
in mouse models of breast-, bladder- and lung cancers 
(Chen et al., 2005; Wang et al., 2010; Feng et al., 2011).
Recent data showed that the tumor-derived lymphangi-
ogenic growth factors are transported through the lym-
phatics and lead to expansion of the lymphatic network in 
the draining lymph nodes before the actual metastasis oc-
curs, thereby preparing a premetastatic niche, enabling the 
seeding of tumor cells to the dLN (Liersch et al., 2012).
In addition to animal models, there are an impressive 
number of studies on patients suffering from gastric car-
cinoma, melanoma and breast cancer, showing a close 
Figure 1.The role of VEGF-c in cancer metastasis is the promotion of tumor-associated lymphangiogensis. Based on Alitalo et al., 
2005.
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correlation between the serum level of VEGF-C, the 
density of lymphatic vessels and the incidence of lymph 
node metastases (Gao et al., 2009; Cianfarani et al., 2012; 
Ding et al., 2012). In addition to VEGF-C and VEGF-
D, also other factors, such as VEGF-A, FGF, ANG-2, 
and HGF may control the process of lymphangiogenesis 
and lymphatic metastasis (Achen & Stacker, 2006).
Today, it is clear that both angiogenesis and lym-
phangiogenesis may serve as excellent targets for cancer 
therapies. The antiangiogenic therapies are already evalu-
ated in medical procedures while antilymphangiogenic 
therapies are still at the stage of preclinical and clinical 
trials.
ANTIBody-BAsEd THERApIEs To INHIBIT 
ANGIoGENEsIs
Several preclinical studies demonstrated that monoclo-
nal antibodies specific for VEGF completely suppressed 
tumor angiogenesis and inhibited the growth of human-
derived tumor cell lines injected into nude mice. These 
results strongly suggested that VEGF inhibitors blocked 
both angiogenesis and tumor growth (Kim et al., 1993; 
Warren et al., 1995; Borgstrom et al., 1998) and led to 
development of therapeutic anti-VEGF monoclonal an-
tibodies.
Monoclonal antibody neutralizing VEGF
Bevacizumab (produced by Genentech/Roche and 
distributed under the name Avastin) is a humanized 
monoclonal antibody that specifically recognizes, re-
moves from the circulation and suppresses biological 
activity of human VEGF. In 2004 bevacizumab was 
approved by FDA for treatment of metastatic colorec-
tal cancer (mCRC) and thus became the first antiangio-
genic drug accepted for cancer therapy. Bevacizumab is 
generally well tolerated by patients but sometimes it has 
specific adverse effects, most commonly hypertension, 
proteinuria, bleeding, wound healing complications, and 
thromboembolism (Fox et al., 2007).
After the unsatisfactory results of the initial trials with 
bevacizumab as a single agent (Giantonio et al., 2007) it 
is now most commonly used in combination with cy-
totoxic therapy for treatment of mCRC, non-small cell 
lung cancer, and renal cell cancer (Roche, Avastin pre-
scribing information, 20131), while the use of bevaci-
zumab as a single agent is limited to the palliative treat-
ment of patients suffering from glioblastoma multiforme 
(Agha et al., 2010, Chamberlain, 2011). In combination 
with chemotherapy, bevacizumab prolonged progres-
sion-free survival compared to chemotherapy alone, and 
showed meaningful clinical benefits in patients with dif-
ferent tumor types (Kabbinavar et al., 2003; Hurwitz et 
al., 2004; Miller et al., 2007). In 2008 FDA approved 
bevacizumab for treatment of patients with HER2-neg-
ative metastatic breast1 cancer on the basis of previous 
clinical studies that demonstrated an increase in pro-
gression-free survival of patients submitted to combined 
therapy of bevacizumab and paclitaxel (O’Shaughnessy, 
2010; Ocana et al., 2011). However, further clinical trials 
showed that combination of bevacizumab with cytotoxic 
agents did not lead to any increase in overall survival of 
patients with breast cancer and, additionally, this therapy 
was associated with a high risk of severe life threatening 
events, the reasons of which are discussed below. The 
synergistic effect of bevacizumab and chemotherapeutic 
agents observed in some types of tumors is probably as-
sociated with normalization of the tumor vasculature by 
inhibition of VEGF/VEGFR signaling. Elevated level 
of VEGF in tumors leads to disorganization and lack of 
typical hierarchy of tumor blood vessels. It is also re-
ported that high permeability of the tumor vasculature 
and high interstitial fluid pressure (IFP) in tumors results 
from a high VEGF level in the tumor microenviron-
ment. It is believed that VEGF inhibition by bevacizum-
ab causes a decrease in IFP and thus improves transfer 
of chemotherapeutic agents into the tumor (Jain & Car-
meliet, 2001; Gerber & Ferrara, 2005).
The efficiency of bevacizumab in combined therapies 
is constantly under investigation. Preclinical studies dem-
onstrated that bevacizumab might act as a biological en-
hancer of radiation therapy. Experiments performed by 
Gorski and colleagues showed that exposure to ionizing 
radiation (IR) strongly induced VEGF expression in the 
tumor (Gorski et al., 1999), which is regarded as an im-
portant element of tumor resistance to radiation therapy. 
Blockade of tumor angiogenesis with bevacizumab could 
improve the therapeutic efficacy of IR. This strategy, 
however, requires verification in clinical trials (Kim et al., 
2013).
Apart from its role in angiogenesis, VEGF is also an 
important immunomodulatory factor that might have a 
suppressive effect on antitumor immune response. In 
this respect, VEGF induces the activity of regulatory T 
cells (Tregs) (Li et al., 2006) and strongly inhibits dif-
ferentiation of hematopoietic progenitor CD34+ cells 
into conventional dendritic cells by inactivating NF-κB 
transcription factor through VEGFR-1 (Gabrilovich 
et al., 1998; Oyama et al., 1998). Since Tregs can pro-
mote immune suppression and the dendritic cells play an 
important role in host anti-tumor response, high levels 
of VEGF could contribute to tumor immune escape. 
Therefore, inhibition of the VEGF/VEGFR-1 signal-
ing pathway with bevacizumab could be a strategy to 
improve dendritic cell maturation and enhance host im-
mune response to tumor (Osada et al., 2008). Adoptive 
cell transfer (ACT) immunotherapy is a new approach 
involving transfusion of different leukocyte subsets into 
patients in order to eradicate tumor cells with the use of 
immune mechanisms (June, 2007). Based on the fact that 
the ACT strongly depends on the extravasation of the 
leukocytes from tumor vessels into the tumor stroma, it 
can be supposed that the immunological cells adminis-
tered to patients during ACT treatment would be most 
effective in interaction with endothelial cells in normal-
ized vessels. Therefore, it is proposed that treatment 
with anti-VEGF antibodies prior to the ACT procedure 
may have a beneficial effect on the success of the ther-
apy. Such an approach was investigated on the model 
of metastatic melanoma. As shown in studies on ani-
mal models, mAb that blocks VEGF can also normal-
ize tumor vasculature, upregulate endothelial adhesion 
molecules in tumor vessels, and increase the number of 
tumor-infiltrating leukocytes (Mulligan et al., 2009; Shri-
mali et al., 2010). The efficacy of ACT combined with 
anti-VEGF has recently been tested in the therapy of 
human cancer (Kandalaft et al., 2013).
High expectations associated with bevacizumab after 
the positive results of preclinical studies were not ful-
filled. The best clinical effects of bevacizumab are ob-
tained in combination therapy of mCRC. Nevertheless, 
1[online], access on 26.03.2013; www.gene.com/download/pdf/avastin_prescribing.pdf
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even in these cases, bevacizumab is not capable of ar-
resting the progression of the disease and the possible 
long-term effect of the inhibition of VEGF is the devel-
opment of therapy resistance mechanisms in the tumor. 
However, it should be emphasized that bevacizumab is 
recommended for patients with advanced and metastatic 
cancers and it cannot be excluded that its effectiveness 
could be greater if the therapeutic was applied at less ad-
vanced stages of the disease.
Monoclonal antibodies blocking VEGFR
Another strategy for suppression of VEGF/VEGFR 
signaling involves monoclonal antibodies targeting recep-
tors for VEGF. Animal studies with a rat MF1/IMC-
18F1 mAb (developed by ImClone Systems) specific to 
VEGFR-1 demonstrated that suppression of this recep-
tor effectively blocked tumor angiogenesis and metastasis 
(Luttun et al., 2002). Later, the same company generated 
a fully human mAb (IMC-18F1) specific to VEGFR-1, 
the antiangiogenic and tumoricidal activity of which was 
tested both in vitro and in vivo on human breast carcino-
ma models. Results of these studies showed that IMC-
18F1 inhibited VEGF, VEGF-B and PlGF binding to 
VEGFR-1, thus suppressing tumor growth (Wu et al., 
2006). The antiangiogenic and tumor-suppressing activ-
ity of IMC-18F1 is being evaluated in an ongoing Phase 
2 clinical trial. Encouraging results of studies on VEG-
FR-1 inhibitor inspired ImClone Systems to develop 
mAb specific to VEGFR-2: IMC-1121B (ramucirumab) 
is a human mAb which binds to the extracellular domain 
of VEGFR-2. Anticancer efficacy of ramucirumab was 
verified in completed Phase 1 clinical trials, which were 
carried out on patients with melanoma, gastric adeno-
carcinoma, uterine leiomyosarcoma and renal cancer. At 
present, ramucirumab is tested in Phase 2 and 3 clini-
cal trials as a single agent or combined with paclitaxel, 
docetaxel, carboplatin, or other cytotoxic drugs (Zhu et 
al., 2003).
In October 2012 Eli Lilly, Inc. (ImClone Systems) an-
nounced the results of the REGARD trial, which was 
one of the two ramucirumab Phase 3 studies on ad-
vanced gastric cancer. It showed that ramucirumab used 
as a single agent statistically improved overall survival 
and prolonged progression-free survival of patients with 
advanced gastric cancer. The ongoing Phase 3 RAIN-
BOW study is carried out to verify clinical activity of ra-
mucirumab combined with paclitaxel in metastatic gastric 
cancer2. It is noteworthy that AVAGAST, a similar study 
in which bevacizumab was tested in combination with 
first-line chemotherapy on gastric cancer, did not meet 
its primary endpoint of extending overall survival in pa-
tients. The still unanswered question is whether the ther-
apy with ramucirumab could show actual clinical benefit 
in cancer types where bevacizumab was not successful 
(Ohtsu et al., 2011).
Tumor resistance to antiangiogenic therapy targeting 
VEGF/VEGFR
Resistance to therapy is a major clinical problem that 
strongly affects successful treatment of patients with 
cancers (Lee et al., 2012). Antiangiogenic therapy was 
developed as a novel anticancer strategy in the hope to 
avoid the problems of tumor resistance because it targets 
stable endothelial cells instead of unstable tumor cells 
(Kerbel, 1991; Boehm et al., 1997). Since clinical studies 
with bevacizumab revealed limited therapeutic efficacy of 
this drug, at least two important questions were raised: 
firstly, whether the tumor could develop resistance to 
antiangiogenic agents; and secondly, if such resistance 
might be considered as a major reason for the failure of 
this therapy. Recent data indicate that tumor progression 
after antiangiogenic treatment can be the result of dif-
ferent mechanisms of adaptation depending on tumor 
type and microenvironment, which involve both tumor 
cells and stromal components (for review see Grepin & 
Pages, 2010; Loges et al., 2010).
selection of more invasive tumor cells2
Several months after FDA revoked the approval 
for bevacizumab for treatment of metastatic breast 
cancer, Conley and colleagues from the University of 
Michigan Department of Internal Medicine published 
results of studies performed in order to elucidate po-
tential reasons of the limited efficacy of antiangiogen-
ic drugs. They hypothesized that the highly metastatic 
cancer stem cells (CSCs) play a crucial role in the ac-
celeration of tumor growth, observed very often after 
antiangiogenic treatments (Burstein et al., 2008). Us-
ing mouse model of human breast cancer, they dem-
onstrated that administration of antiangiogenic agents 
such as bevacizumab or sunitinib (receptor tyrosine 
kinase inhibitor) leads to the generation of hypoxia 
within the tumor tissue. This activates hypoxia-induc-
ible factor 1α, which increases the number of CSCs 
in the tumor. Accelerated regrowth of breast tumors 
results from an increase in the aggressive breast CSCs 
population (Conley et al., 2012). Authors of the above-
mentioned studies claim that a combined therapy tar-
geting both the tumor vasculature and CSCs might 
overcome tumor resistance to antiangiogenic agents.
Angiogenic redundancy
The VEGF/VEGFR signaling pathway plays a pre-
dominant role in tumor angiogenesis. However, it is 
clear that this process is also regulated by many other 
factors. When VEGF-dependent angiogenesis is blocked 
by agents such as bevacizumab or sunitinib, the tumor 
adaptation involves upregulation of other proangiogenic 
stimulators including VEGF-B, PlGF, TNF, fibroblast 
growth factors (FGFs), plateled-derived growth factor 
(PDGF), angiopoietin 1 and 2, ephrins, TGF-α, TGF-β, 
or HB-EGF (Casanovas et al., 2005; Fischer et al., 2008; 
You & McDonald, 2008; Acevedo et al., 2009; Lieu et al., 
2011). It is thought that targeting more than one angio-
genic pathway at the same time could prevent angiogenic 
redundancy and increase anticancer activity of antiangio-
genic therapies (Gossage & Eisen, 2010).
Many studies indicate that EGFR signaling strongly 
contributes to tumor angiogenesis (Ellis, 2004). The epi-
dermal growth factor receptor (EGFR) family consists of 
four members (EGFR, ErbB2, ErbB3, and ErbB4; fur-
ther referred to as EGFRs) that are activated upon bind-
ing of the EGF- family ligands (EGF, TGF-α, HB-EGF, 
amphiregulin, neuregulin). EGFRs, as well as EGF-fam-
ily ligands, are overexpressed in numerous solid tumor 
types (Laskin & Sandler, 2004; Laskin & Sandler, 2004) 
and in tumor endothelium (Amin et al., 2006; Amin et 
al., 2008). Activation of EGFRs by their ligands is gener-
2[online] access on 26.03.2013; www.targetedhc.com/articles/Ramucirumab-Achieves-Primary-Endpoint-as-Single-Agent-in-Metastatic-Gas-
tric-Cancer
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ally accepted as crucial for tumor progression and me-
tastasis because it stimulates multiple signaling pathways 
leading to increased cell survival, proliferation, and mo-
tility (Yarden, 2001). EGFRs signaling regulates the ex-
pression of several key proangiogenic factors, including 
VEGF, chemokine (C-X-C motif) ligand 8 (CXCL8), 
and basic fibroblast growth factor (bFGF) (Goldman et 
al., 1993), as summarized in Fig. 2. In preclinical models, 
suppression of EGFR signaling resulted in downregu-
lation of proangiogenic factors and decrease in tumor 
blood vessel density as well as metastasis (Ellis, 2004). It 
has been recently demonstrated that EGFR is activated 
on stromal cells in bevacizumab-resistant tumors and 
that the combined therapy with bevacizumab and erlo-
tinib (small-molecule EGFR tyrosine kinase inhibitor) 
may delay tumor adaptation to antiangiogenic treatment 
(Cascone et al., 2011).
Presently, two therapeutic monoclonal antibodies spe-
cific to EGFR, cetuximab and panitumumab, are ap-
proved for treatment in patients with cancer. Cetuximab 
(distributed as Erbitux, marketed by Merck Serono) is a 
human-murine chimeric monoclonal antibody that binds 
to the extracellular domain of human EGFR hindering 
its activation. It was approved by FDA in 2004 for treat-
ment of patients with EGFR-expressing, KRAS wild-
type mCRC as well as head and neck cancer (Jonker et 
al., 2007; Bonner et al., 2010).
In vitro and in vivo studies showed that the anticancer 
activity of cetuximab probably results from direct sup-
pression of EGFR signaling and involves inhibition of 
cell cycle progression (Wu et al., 1995), angiogenesis and 
invasion (Perrotte et al., 1999). The Fc fragment of ce-
tuximab (an IgG1 class antibody) may also trigger im-
mune mechanisms such as antibody-dependent cell-me-
diated cytotoxicity (ADCC) and complement-dependent 
cytolysis (CDC). Intravenous administration of cetuxi-
mab may result, in some patients, in a severe infusion 
reaction due to the presence of mouse protein sequences 
(Patel & Goldberg, 2006). However, anti-EGFR thera-
py can be also conducted with a fully human antibody, 
panitumumab (distributed as Vectibix, marketed by Am-
gen) (Heun & Holen, 2007; Keating, 2010). Both these 
anti-EGFR mAbs have proven their clinical usefulness. 
Nevertheless, tumor drug resistance remains a serious 
clinical problem that strongly affects their therapeutic 
efficacy. The mechanism of resistance to anti-EGFR 
therapy is not yet understood but some data indicate 
a potential role of VEGF in that process. Viloria-Petit 
et al. demonstrated that tumors that developed resist-
ance to cetuximab overexpressed VEGF (Viloria-Petit 
et al., 2001). Other studies showed increased expression 
of VEGFR-1 and VEGFR-2 on resistant tumor cells 
and also confirmed an important role of the VEGF/
VEGFR signaling pathway in the development of resist-
ance to the anti-EGFR antibody (Ciardiello et al., 2004; 
Bianco et al., 2008). Interference and cross-talk between 
the VEGFR and EGFR signaling axes led to the as-
sumption that they might constitute a very attractive tar-
get for combined therapy. Preclinical studies confirmed 
that simultaneous suppression of EGFR signaling by a 
monoclonal antibody and inhibition of VEGF secretion 
by VEGF antisense oligonucleotides prolonged tumor 
growth inhibition as compared to controls (monoclonal 
anti-EGFR antibody alone, or VEGF antisense oligo-
nucleotide alone) (Ciardiello et al., 2000). The results of 
the BOND2 trial, which tested the anticancer activity of 
cetuximab combined with bevacizumab in patients with 
advanced mCRC, were also promising (Saltz et al., 2007). 
Alas, further studies did not confirm clinical benefits of 
such a strategy: results of the CAIRO2 study (combina-
tion of bevacizumab and cetuximab with chemotherapy) 
and the PACCE study (combination of bevacizumab 
and panitumumab with chemotherapy) revealed that the 
combined anti-VEGF and anti-EGFR monoclonal an-
tibody- based treatment merged with chemotherapy re-
sulted in a statistically decreased progression-free survival 
in patients with advanced colorectal cancer (Hecht et al., 
2009; Tol et al., 2009).
To summarize, despite significant progress in under-
standing the mechanism of angiogenesis and in pro-
Figure 2. The interconnection of EGFR and VEGF pathways with respect to angiogenesis. 
Simultaneous blockade of these signaling pathways by monoclonal antibodies was tested to target tumors in therapies. Based on Alitalo 
et al., 2005.
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duction of different types of antibodies to inhibit this 
process, success in overcoming angiogenesis-dependent 
tumor growth and metastasis is a still unattained goal. 
In the context of tumor metastasis, merging antiangio-
genic therapies with strategies targeting another route of 
cancer dissemination, the lymphatic vessel system, might 
have favorable outcomes. Inhibition of tumor metastasis 
through blood vessels, while the lymphatic vessel system 
is still unimpaired by treatment, may not be enough to 
prevent cancer dissemination.
ANTIBody-BAsEd THERApIEs To INHIBIT 
lyMpHANGIoGENEsIs
Monoclonal antibodies blocking VEGFR-3
Since VEGF-C and VEGF-D, and their receptors 
were the first identified factors that drive tumor lym-
phangiogenesis, the first neutralizing antibodies were 
directed towards the VEGF-C/VEGF-D/VEGFR-3 
signaling axis components. Pytowski et al. produced 
mF4-31C1, an anti-VEGFR-3 mAb that antagonized the 
binding of VEGF-C to this receptor. Administered into 
mice, this mAb potently inhibited formation of new lym-
phatic vessels, without affecting the preexisting ones (Py-
towski et al., 2005). Another anti-VEGFR-3 mAb, hF4-
3C5, was produced by Persaud et al. This mAb binds to 
VEGFR-3 with high affinity and blocks its interaction 
with VEGF-C (Persaud et al., 2004). Subsequently, Jime-
nez et al. produced a more sophisticated antibody — a 
bispecific antibody (diabody), which simultaneously binds 
to VEGFR-2 and VEGFR-3, and blocks their interac-
tion with VEGF and VEGF-C. In in vitro studies, this 
diabody inhibited both VEGF- and VEGF-C-stimulated 
migration of endothelial cells. Diabodies directed against 
two different tumor-associated targets, are supposed to 
have enhanced therapeutic activity (Jimenez et al., 2005).
All mAbs described above inhibit ligand binding to 
VEGFR-3. The outcome of this inhibition depends on 
mAb affinity and on the ratio of concentrations of the 
VEGF family ligand and the antibody, since the anti-
body competes with the ligand for receptor binding. 
High ligand-to-antibody ratio could decrease the block-
ing efficacy of mAb directed against ligand binding sites 
in the receptor. To overcome this problem, Tvorogov et 
al. (2010) produced an anti-VEGFR-3 mAb that blocks 
dimerization of the receptor and thus abrogates signal 
generation in a ligand concentration-independent man-
ner. Since elevated inhibitory activity and better thera-
peutic outcome is expected from therapies utilizing 
combinations of antibodies, this group combined an an-
ti-dimerization antibody with an antibody which blocks 
ligand binding. In this configuration the inhibitory ef-
fect on sprouting, migration and in vivo tube formation 
by microvascular endothelial cells was more pronounced 
(Tvorogov et al., 2010).
Anti-VEGFR-3 therapies are of great importance due 
to the fact that, in addition to expression on lymphatic 
vessels, VEGFR-3 is also expressed on tumor microvas-
culature in angiogenic sprouts. Antibodies which block 
the ligand binding site of VEGFR-3 significantly reduce 
blood vessel density and sprouting. Thus, anti-VEGFR-3 
mAbs not only reduce lymphangiogenesis but might also 
be beneficial in antiangiogenic therapies, especially in 
combination with anti-VEGFR-2 mAbs (Tammela et al., 
2008).
To our knowledge, despite encouraging in vitro and 
in vivo results, only one anti-VEGFR-3 antibody, IMC-
3C5, produced by ImClone LLC, has entered Phase 1 
clinical trials. The results of these studies are supposed 
to be completed by the end of 2013 (ClinicalTrials.gov 
identifier: NTC01288989). IMC-3C5 combined with clas-
sical chemotherapy demonstrated significant inhibition of 
tumor growth in animal models of lung and head and 
neck cancers. The inhibitory effect of combined treat-
ment surpasses that of either agent alone. Thus, IMC-
3C5 is supposed to improve today’s chemotherapy treat-
ment3.
Monoclonal antibodies neutralizing VEGF-c and VEGF-d
Neutralization of VEGF-C and VEGF-D is another 
approach to inhibit lymphangiogenesis through inter-
ference with the VEGF-C/VEGF-D/VEGFR-3 sign-
aling axis. As the mature form of VEGF-C can signal 
through both VEGFR-3 and VEGFR-2 (Plate, 2001), 
inhibition of VEGF-C may have an impact not only on 
lymphangiogenesis but on angiogenesis as well. One of 
the antibodies produced to achieve this goal, an scFv-
format anti-VEGF-C antibody binding to an epitope 
that is important for receptor binding, was generated by 
Rinderknecht et al. (Rinderknecht et al., 2010). Two years 
later, Kashima et al. produced an anti-VEGF-D antibody 
(cVE199) inhibiting the binding of VEGF-D to VEG-
FR-3. The inhibitory activity of this antibody was con-
firmed in vitro and in vivo on a model of neuroblastoma. 
cVE199 significantly inhibits both lymphangiogenesis 
and lymphatic metastasis (Kashima et al., 2012).
Until now, only one anti-VEGF-C antibody has been 
translated from preclinical studies into a clinical devel-
opment stage: VGX-100 (produced by Circadian Tech-
nologies Limited) entered Phase 1 clinical trials4 in 2012. 
VGX-100 combined with bevacizumab and/or chemo-
therapy significantly decreased the growth of tumors in 
the animal models of glioblastoma, prostate cancer and 
pancreatic cancer.
Antibodies binding newly recognized 
prolymphangiogenic factors3,4
With meaningful progress in the field of lymphangi-
ogenesis, more factors stimulating this process have been 
identified. Since in vitro and in vivo data confirmed their 
contribution to lymphatic vessel metastasis, they are now 
considered potential therapeutic targets. One such newly 
identified prolymphangiogenic factor is ephrin-B2. Block-
ing ephrin-B2 with scFv antibody fragments leads to in-
hibition of endothelial cell migration and tube formation 
in in vitro studies, which is in agreement with the obser-
vation that in xenografted mice this approach resulted in 
reduction in blood and lymphatic vessel density (Aben-
gozar et al., 2012). Another potential target for blocking 
lymphangiogenesis is Nrp2. Anti-Nrp2 antibody that in-
hibits the binding of VEGF-C to Nrp2 and blocks the 
formation of the Nrp2-VEGFR-3 complex significantly 
suppresses LEC migration as well as tumor-dependent 
3[online] access on 26.03.2013; www.circadian.com.au/sites/default/files/Circadian%20partner%20ImClone%20Systems%20demon-
strates%20VEG FR-3%20antibody%20improves%20anti-tumour%20effects%20of%20chemotherapy%20in%20mouse%20tumour%20mod-
els.pdf
4[online], access on 26.03.2013; www.businesswire.com/cgi-bin/mmg.cgi?eid=6250628&lang=en
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lymphangiogenesis and lymph node metastasis (Caunt et 
al., 2008).
Although impressive progress has been made in iden-
tifying prolymphangiogenic factors as well as in genera-
tion of neutralizing mAbs with evident efficiency in pre-
clinical studies, only two of these products entered Phase 
1 clinical trials.
coNclusIoNs
Although major progress has been made in the vas-
cular biology and theories connecting lymphangiogen-
esis and angiogenesis with tumor progression and me-
tastasis have been proposed, clinical solutions based on 
these findings usually show little or no therapeutic effect 
on cancers when antiangiogenic or antilymphangiogenic 
factors are used as single agents. Preclinical and clinical 
studies demonstrate that normalization of tumor blood 
vessels and inhibition of tumor-induced lymphatic for-
mation with the use of antiangiogenic and antilymphang-
iogenic therapeutic monoclonal antibodies seems to be a 
valid direction in cancer treatment when combined with 
other antitumor agents. This strategy might improve the 
efficiency of chemotherapy, radiotherapy, and immuno-
therapy based on the ACT. As the molecular pathogen-
esis of cancers is a matter of extreme complexity, the 
changes leading to malignant transformation may involve 
both (i) extracellular and membrane-associated molecules 
(such as the growth factors and their receptors), and (ii) 
intracellular factors and effector molecules responsible 
for the metastatic properties of tumor cells.
An important issue, resulting directly from the above-
described diversity of mechanisms of malignancy, is 
the problem of proper patient selection for clinical tri-
als. Only patients that, according to the current state of 
knowledge, can be cured using therapeutics acting on 
extracellular and membrane-associated targets, should be 
chosen. This demonstrates the need to find new molec-
ular biomarkers that would ideally give an insight into 
the pathogenesis of each particular case of the malignant 
disease and help to assess the chances of recovery, to 
choose an appropriate therapy, and to monitor changes 
in the tumor throughout the treatment.
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